Category Business

Update to contractual arrangements between AstraZeneca, Swedish Orphan Biovitrum AB and Sanofi

Update to contractual arrangements between AstraZeneca, Swedish Orphan Biovitrum AB and Sanofi AstraZeneca, Swedish Orphan Biovitrum AB (publ) (Sobi) and Sanofi have updated and simplified their contractual arrangements relating to the development and commercialisation of nirsevimab in the US. Given…

Read MoreUpdate to contractual arrangements between AstraZeneca, Swedish Orphan Biovitrum AB and Sanofi

Johnson & Johnson Subsidiary LTL Management LLC (“LTL”) Re-Files for Voluntary Chapter 11 to Equitably Resolve All Current and Future Talc Claims

Johnson & Johnson Subsidiary LTL Management LLC (“LTL”) Re-Files for Voluntary Chapter 11 to Equitably Resolve All Current and Future Talc Claims Johnson & Johnson (NYSE:JNJ) (the Company) today announced that its subsidiary LTL Management LLC (LTL) has re-filed for…

Read MoreJohnson & Johnson Subsidiary LTL Management LLC (“LTL”) Re-Files for Voluntary Chapter 11 to Equitably Resolve All Current and Future Talc Claims

Aspect Biosystems and Novo Nordisk enter partnership to develop bioprinted tissue therapeutics for diabetes and obesity

Aspect Biosystems and Novo Nordisk enter partnership to develop bioprinted tissue therapeutics for diabetes and obesity Aspect Biosystems and Novo Nordisk A/S today announced a collaboration, development, and licence agreement to develop bioprinted tissue therapeutics designed to replace, repair, or…

Read MoreAspect Biosystems and Novo Nordisk enter partnership to develop bioprinted tissue therapeutics for diabetes and obesity

Sandoz receives approval by European Commission for Hyrimoz® (adalimumab) high-concentration formulation

Sandoz receives approval by European Commission for Hyrimoz® (adalimumab) high-concentration formulation Sandoz, a global leader in off-patent (generic and biosimilar) medicines, today announced that the European Commission (EC) granted marketing authorization in the European Union (EU) for a citrate-free high…

Read MoreSandoz receives approval by European Commission for Hyrimoz® (adalimumab) high-concentration formulation

Lilly to Make Record-Breaking Investment in Indiana Manufacturing Facilities

Lilly to Make Record-Breaking Investment in Indiana Manufacturing Facilities Eli Lilly and Company (NYSE: LLY) announced today that it will invest an additional $1.6 billion and add another 200 new jobs at its two new manufacturing sites within LEAP Innovation Park in Boone County, bringing the…

Read MoreLilly to Make Record-Breaking Investment in Indiana Manufacturing Facilities